Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma Ryoichi Sawada 1 , Yoshitaka Honma 1 , Hirokazu Syoji 1 , Atsuo Takashima 1 , Satoru Iwasa 1 , Natsuko Okita 1 , Ken Kato 1 , Tetsuya Hamaguchi 1 , Yasuhide Yamada 1 , Yoshinori Ito 2 , Yasuhiro Shimada 1 1National Cancer Center Hospital, Gastrointestinal Oncology Division, Tokyo 2National Cancer Center Hospital, Radiation Oncology Division, Tokyo Keyword: 食道扁平上皮癌 , Stage I , 化学放射線療法 , 5-FU , シスプラチン pp.1285-1289
Published Date 2013/8/25
DOI https://doi.org/10.11477/mf.1403113917
  • Abstract
  • Look Inside
  • Reference

 Patients with resectable ESCC(esophageal squamous cell cancer)are generally treated by esophagectomy with prophylactic three-field lymphadenectomy in Japan. On the other hand, for patients with advanced ESCC, the efficacy of concurrent chemoradiotherapy has already been demonstrated.

 According to a result of phase II trial of chemoradiotherapy for Stage I ESCC(JCOG9708)demonstrated the high efficacy and survival proportion, and phase III trial which evaluates non-inferiority of concurrent chemoradiotherapy compared with esophagectomy is now in progress.

 Recently, thanks to development of endoscopic mucosal resection, pathological non-curative cases after endoscopic treatment are increasing. As an additional treatment for these cases, phase II trial which evaluates the efficacy of treatment strategy of endoscopic resection followed by prophylactic chemoradiotherapy is also now in progress.

Copyright © 2013, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院